Toxoplasmosis Treatment Market By Type (Acquired Toxoplasmosis, Congenital Toxoplasmosis), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Toxoplasmosis Treatment Market

The toxoplasmosis disease is a transmitted disease, which is transferred from animal to human, or mother to child during pregnancy, and can spread through cat feces or contaminated food. It is caused by single celled parasite known as Toxoplasma gondii, which is a protozoan parasite that infects most species of warm-blooded animals, including humans and causes the disease toxoplasmosis.

Toxoplasmosis treatment includes inhibitors of dihydrofolate reductase (DHFR) (pyrimethamine and trimethoprim), and dihydropteroate synthetase (sulfonamides, such as sulfadiazine, sulfamethoxazole, and sulfadoxine), which block the folic acid synthesis. This treatment is used in patients who are suffering from parasitic infection (toxoplasmosis disease) and mostly it is used in pregnant women and infants.

Toxoplasmosis treatment market trends which drive growth of market include rise in government awareness programs for toxoplasmosis and continuous increase in unhygienic environment in popular countries. In addition, major players are investing in development and commercialization of toxoplasmosis products to decrease incidences of toxoplasmosis disease that fuel the growth of market.

Moreover, Increase in number of chemotherapy procedures can lead to rise in number of toxoplasmosis infection, thereby boosting the growth toxoplasmosis treatment market forecast. Furthermore, toxoplasma IgG immunoglobulin level rises by 4 times higher in cancer patients which causes toxoplasmosis. Thus, rise in incidences of cancer disease increases the demand for toxoplasmosis treatment and further boosts the market growth. 

Depending on type, the market is bifurcated into acquired toxoplasmosis and congenital toxoplasmosis. The acquired toxoplasmosis segment exhibited largest toxoplasmosis treatment market share in 2021, owing to rise in prevalence of acquired toxoplasmosis caused due to accidental consumption of oocysts after coming into contact with or consuming something that has contact with toxoplasma-infected cat feces.

On the basis of route of administration, the market is segmented into oral and parenteral. The oral segment exhibited highest growth in 2021 and is expected to remain dominant during the forecast period, owing to advantages associated with oral route such as more pre-determined doses, convenience, patient self-administration, and easy to administer. For instance, Dr. Reddy's Laboratories Ltd. have the product Pyrimethamine Tablets USP, 25 mg, (Daraprim) which is available in oral form.

On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The hospital pharmacies segment dominated the toxoplasmosis treatment market in 2021, owing to factors such as large number of patient visits to the hospital pharmacies as they offer the precise drug according to status of disease of patient and easy accessibility of the facilities.

Moreover, the online providers segment is projected to register a CAGR of 6.3% during the forecast period, owing to rise in digitalization around the globe. In addition, availability of a variety of toxoplasmosis drugs such as Daraprim on e-commerce platforms is more than pharmacies or retail stores, which helps patients buy products at ease propel the segment growth.

Region wise, North America had the highest toxoplasmosis treatment market share in 2021. This was attributed to rise in cases of parasitic infection cause the toxoplasmosis disease. In addition, strong presence of key players such as Alvogen, Oakrum Pharma, and Vyera Pharmaceuticals LLC that offers the toxoplasmosis treatment further boost the market growth in the region.

However, Asia-Pacific is expected to witness highest growth during the forecast period, owing to rise in prevalence of toxoplasmosis infection. In addition, rise in awareness programs for toxoplasmosis disease further boosts the toxoplasmosis treatment market size growth in this region.

Key findings of the study

• By type, the acquired toxoplasmosis segment was highest contributor to the toxoplasmosis treatment industry in 2021. However, the congenital toxoplasmosis segment is anticipated to grow at the highest CAGR during the forecast period.

• On the basis of route of administration, the oral segment was dominated the toxoplasmosis treatment industry in 2021.

• By distribution channel, the hospital pharmacies segment dominated the market in 2021. However, online providers segment is anticipated to grow at the highest CAGR during the forecast period.

• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the toxoplasmosis treatment market analysis.

Overview

The global toxoplasmosis treatment market was valued at $683.11 million in 2021, and is projected to reach $1,093.88 million by 2031, registering a CAGR of 4.8% from 2022 to 2031. Toxoplasmosis is a disease that occurs due to Toxoplasma gondii parasite, which is one of the world's most common parasites. This infection usually occurs by eating undercooked contaminated meat, exposure from infected cat feces, or mother-to-child transmission during pregnancy. Toxoplasmosis may cause flu-like symptoms in some people, however majority of those infected never show any signs or symptoms.

The growth of global toxoplasmosis treatment market is majorly driven by increase in prevalence of foodborne illness. In addition, technological advancement in treatment and diagnosis for toxoplasmosis disease propels the market growth. Furthermore, increase in awareness regarding toxoplasmosis treatment in developed countries such as the U.S. further fuels the market growth.

In addition, increase in prevalence of HIV across the globe has increased the risk of toxoplasma gondii infection due to less immune response in HIV infected patients that lead to rise in demand for toxoplasmosis treatment and propels the market growth. For instance, according to the World Health Organization (WHO), by the end of 2021, around 38.4 million people were living with HIV across the globe, therefore it is expected to increase the prevalence of toxoplasmosis infection among the global population that drives the market growth.

Furthermore, surge in healthcare, industrial development, and investments by the government and private organizations in Asia-Pacific, along with rise in awareness regarding toxoplasmosis disease is anticipated to positively impact the market during the forecast period. Moreover, product launch for toxoplasmosis treatment by the key market players are the boosting factors for the market growth. For instance, Dr. Reddy's Laboratories Ltd. announced the launch of pyrimethamine tablet USP, 25 mg, approved by the U.S. Food and Drug Administration (USFDA) for the treatment of toxoplasmosis.

However, side effects of toxoplasmosis drugs and high cost of treatment hinder the market growth. Conversely, rise in product approvals for toxoplasmosis treatment is anticipated to provide lucrative opportunities to the market players.

The toxoplasmosis treatment market is segmented on the basis of type, route of administration, distribution channel, and region. By type, the market is categorized into acquired toxoplasmosis and congenital toxoplasmosis. On the basis of route of administration, the market is segregated into oral and parenteral. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global toxoplasmosis treatment market are Alvogen, Dr. Reddy's Laboratories Ltd., Kaiser Permanente, Mangalam Drugs and Organics Ltd., Manus Aktteva Biopharma LLP, Oakrum Pharma, Omicron pharmaceuticals, Teva Pharmaceutical Industries Ltd., Vyera Pharmaceuticals LLC, and Zorish Healthcare Private Limited. 

 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the toxoplasmosis treatment market analysis from 2021 to 2031 to identify the prevailing toxoplasmosis treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the toxoplasmosis treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global toxoplasmosis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Manus Aktteva Biopharma LL

Scope of Toxoplasmosis Treatment Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Acquired Toxoplasmosis

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.3 Congenital Toxoplasmosis

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Oral

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3 Parenteral

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospital Pharmacies

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market share analysis by country

6.3 Drug Stores and Retail Pharmacies

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market share analysis by country

6.4 Online Providers

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market share analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Type

7.2.3 North America Market size and forecast, by Route of Administration

7.2.4 North America Market size and forecast, by Distribution Channel

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Key market trends, growth factors and opportunities

7.2.5.1.2 Market size and forecast, by Type

7.2.5.1.3 Market size and forecast, by Route of Administration

7.2.5.1.4 Market size and forecast, by Distribution Channel

7.2.5.2 Canada

7.2.5.2.1 Key market trends, growth factors and opportunities

7.2.5.2.2 Market size and forecast, by Type

7.2.5.2.3 Market size and forecast, by Route of Administration

7.2.5.2.4 Market size and forecast, by Distribution Channel

7.2.5.3 Mexico

7.2.5.3.1 Key market trends, growth factors and opportunities

7.2.5.3.2 Market size and forecast, by Type

7.2.5.3.3 Market size and forecast, by Route of Administration

7.2.5.3.4 Market size and forecast, by Distribution Channel

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Type

7.3.3 Europe Market size and forecast, by Route of Administration

7.3.4 Europe Market size and forecast, by Distribution Channel

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Key market trends, growth factors and opportunities

7.3.5.1.2 Market size and forecast, by Type

7.3.5.1.3 Market size and forecast, by Route of Administration

7.3.5.1.4 Market size and forecast, by Distribution Channel

7.3.5.2 France

7.3.5.2.1 Key market trends, growth factors and opportunities

7.3.5.2.2 Market size and forecast, by Type

7.3.5.2.3 Market size and forecast, by Route of Administration

7.3.5.2.4 Market size and forecast, by Distribution Channel

7.3.5.3 UK

7.3.5.3.1 Key market trends, growth factors and opportunities

7.3.5.3.2 Market size and forecast, by Type

7.3.5.3.3 Market size and forecast, by Route of Administration

7.3.5.3.4 Market size and forecast, by Distribution Channel

7.3.5.4 Italy

7.3.5.4.1 Key market trends, growth factors and opportunities

7.3.5.4.2 Market size and forecast, by Type

7.3.5.4.3 Market size and forecast, by Route of Administration

7.3.5.4.4 Market size and forecast, by Distribution Channel

7.3.5.5 Spain

7.3.5.5.1 Key market trends, growth factors and opportunities

7.3.5.5.2 Market size and forecast, by Type

7.3.5.5.3 Market size and forecast, by Route of Administration

7.3.5.5.4 Market size and forecast, by Distribution Channel

7.3.5.6 Rest of Europe

7.3.5.6.1 Key market trends, growth factors and opportunities

7.3.5.6.2 Market size and forecast, by Type

7.3.5.6.3 Market size and forecast, by Route of Administration

7.3.5.6.4 Market size and forecast, by Distribution Channel

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Type

7.4.3 Asia-Pacific Market size and forecast, by Route of Administration

7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Key market trends, growth factors and opportunities

7.4.5.1.2 Market size and forecast, by Type

7.4.5.1.3 Market size and forecast, by Route of Administration

7.4.5.1.4 Market size and forecast, by Distribution Channel

7.4.5.2 China

7.4.5.2.1 Key market trends, growth factors and opportunities

7.4.5.2.2 Market size and forecast, by Type

7.4.5.2.3 Market size and forecast, by Route of Administration

7.4.5.2.4 Market size and forecast, by Distribution Channel

7.4.5.3 India

7.4.5.3.1 Key market trends, growth factors and opportunities

7.4.5.3.2 Market size and forecast, by Type

7.4.5.3.3 Market size and forecast, by Route of Administration

7.4.5.3.4 Market size and forecast, by Distribution Channel

7.4.5.4 Australia

7.4.5.4.1 Key market trends, growth factors and opportunities

7.4.5.4.2 Market size and forecast, by Type

7.4.5.4.3 Market size and forecast, by Route of Administration

7.4.5.4.4 Market size and forecast, by Distribution Channel

7.4.5.5 South Korea

7.4.5.5.1 Key market trends, growth factors and opportunities

7.4.5.5.2 Market size and forecast, by Type

7.4.5.5.3 Market size and forecast, by Route of Administration

7.4.5.5.4 Market size and forecast, by Distribution Channel

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Key market trends, growth factors and opportunities

7.4.5.6.2 Market size and forecast, by Type

7.4.5.6.3 Market size and forecast, by Route of Administration

7.4.5.6.4 Market size and forecast, by Distribution Channel

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Type

7.5.3 LAMEA Market size and forecast, by Route of Administration

7.5.4 LAMEA Market size and forecast, by Distribution Channel

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Key market trends, growth factors and opportunities

7.5.5.1.2 Market size and forecast, by Type

7.5.5.1.3 Market size and forecast, by Route of Administration

7.5.5.1.4 Market size and forecast, by Distribution Channel

7.5.5.2 Saudi Arabia

7.5.5.2.1 Key market trends, growth factors and opportunities

7.5.5.2.2 Market size and forecast, by Type

7.5.5.2.3 Market size and forecast, by Route of Administration

7.5.5.2.4 Market size and forecast, by Distribution Channel

7.5.5.3 South Arabia

7.5.5.3.1 Key market trends, growth factors and opportunities

7.5.5.3.2 Market size and forecast, by Type

7.5.5.3.3 Market size and forecast, by Route of Administration

7.5.5.3.4 Market size and forecast, by Distribution Channel

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Key market trends, growth factors and opportunities

7.5.5.4.2 Market size and forecast, by Type

7.5.5.4.3 Market size and forecast, by Route of Administration

7.5.5.4.4 Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Alvogen

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Dr Reddy's Laboratories Ltd.

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Teva Pharmaceutical Industries Limited

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Vyera Pharmaceuticals LLC

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Mangalam Drugs and Organics Ltd.

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Oakrum Pharma

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Kaiser Permanente

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Zorish Healthcare Private Limited

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 omicron pharmaceuticals

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Manus Aktteva Biopharma LLP

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 2. TOXOPLASMOSIS TREATMENT MARKET FOR ACQUIRED TOXOPLASMOSIS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. TOXOPLASMOSIS TREATMENT MARKET FOR ACQUIRED TOXOPLASMOSIS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 4. TOXOPLASMOSIS TREATMENT MARKET FOR CONGENITAL TOXOPLASMOSIS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 5. TOXOPLASMOSIS TREATMENT MARKET FOR CONGENITAL TOXOPLASMOSIS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 6. GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 7. TOXOPLASMOSIS TREATMENT MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 8. TOXOPLASMOSIS TREATMENT MARKET FOR ORAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 9. TOXOPLASMOSIS TREATMENT MARKET FOR PARENTERAL, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 10. TOXOPLASMOSIS TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 11. GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 12. TOXOPLASMOSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 13. TOXOPLASMOSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 14. TOXOPLASMOSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 15. TOXOPLASMOSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 16. TOXOPLASMOSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 17. TOXOPLASMOSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 18. TOXOPLASMOSIS TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 19. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 20. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 21. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 22. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 23. U.S. TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 24. U.S. TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 25. U.S. TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 26. CANADA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 27. CANADA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 28. CANADA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 29. MEXICO TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 30. MEXICO TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 31. MEXICO TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 32. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 33. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 34. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 35. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 36. GERMANY TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 37. GERMANY TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 38. GERMANY TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 39. FRANCE TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 40. FRANCE TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 41. FRANCE TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 42. UK TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 43. UK TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 44. UK TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 45. ITALY TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 46. ITALY TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 47. ITALY TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 48. SPAIN TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 49. SPAIN TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 50. SPAIN TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 51. REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 52. REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 53. REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 54. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 55. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 56. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 57. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 58. JAPAN TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 59. JAPAN TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 60. JAPAN TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 61. CHINA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 62. CHINA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 63. CHINA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 64. INDIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 65. INDIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 66. INDIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 67. AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 68. AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 69. AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 70. SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 71. SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 72. SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 73. REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 74. REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 75. REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 76. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 77. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 78. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 79. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 80. BRAZIL TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 81. BRAZIL TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 82. BRAZIL TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 83. SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 84. SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 85. SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 86. SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 87. SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 88. SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 89. REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 90. REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 91. REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 92.ALVOGEN: COMPANY SNAPSHOT

TABLE 93.ALVOGEN: OPERATING SEGMENTS

TABLE 94.ALVOGEN: PRODUCT PORTFOLIO

TABLE 95.ALVOGEN: NET SALES

TABLE 96.ALVOGEN: KEY STRATERGIES

TABLE 97.DR REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT

TABLE 98.DR REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS

TABLE 99.DR REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO

TABLE 100.DR REDDY'S LABORATORIES LTD.: NET SALES

TABLE 101.DR REDDY'S LABORATORIES LTD.: KEY STRATERGIES

TABLE 102.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 103.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS

TABLE 104.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 105.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES

TABLE 106.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

TABLE 107.VYERA PHARMACEUTICALS LLC: COMPANY SNAPSHOT

TABLE 108.VYERA PHARMACEUTICALS LLC: OPERATING SEGMENTS

TABLE 109.VYERA PHARMACEUTICALS LLC: PRODUCT PORTFOLIO

TABLE 110.VYERA PHARMACEUTICALS LLC: NET SALES

TABLE 111.VYERA PHARMACEUTICALS LLC: KEY STRATERGIES

TABLE 112.MANGALAM DRUGS AND ORGANICS LTD.: COMPANY SNAPSHOT

TABLE 113.MANGALAM DRUGS AND ORGANICS LTD.: OPERATING SEGMENTS

TABLE 114.MANGALAM DRUGS AND ORGANICS LTD.: PRODUCT PORTFOLIO

TABLE 115.MANGALAM DRUGS AND ORGANICS LTD.: NET SALES

TABLE 116.MANGALAM DRUGS AND ORGANICS LTD.: KEY STRATERGIES

TABLE 117.OAKRUM PHARMA: COMPANY SNAPSHOT

TABLE 118.OAKRUM PHARMA: OPERATING SEGMENTS

TABLE 119.OAKRUM PHARMA: PRODUCT PORTFOLIO

TABLE 120.OAKRUM PHARMA: NET SALES

TABLE 121.OAKRUM PHARMA: KEY STRATERGIES

TABLE 122.KAISER PERMANENTE: COMPANY SNAPSHOT

TABLE 123.KAISER PERMANENTE: OPERATING SEGMENTS

TABLE 124.KAISER PERMANENTE: PRODUCT PORTFOLIO

TABLE 125.KAISER PERMANENTE: NET SALES

TABLE 126.KAISER PERMANENTE: KEY STRATERGIES

TABLE 127.ZORISH HEALTHCARE PRIVATE LIMITED: COMPANY SNAPSHOT

TABLE 128.ZORISH HEALTHCARE PRIVATE LIMITED: OPERATING SEGMENTS

TABLE 129.ZORISH HEALTHCARE PRIVATE LIMITED: PRODUCT PORTFOLIO

TABLE 130.ZORISH HEALTHCARE PRIVATE LIMITED: NET SALES

TABLE 131.ZORISH HEALTHCARE PRIVATE LIMITED: KEY STRATERGIES

TABLE 132.OMICRON PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 133.OMICRON PHARMACEUTICALS: OPERATING SEGMENTS

TABLE 134.OMICRON PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 135.OMICRON PHARMACEUTICALS: NET SALES

TABLE 136.OMICRON PHARMACEUTICALS: KEY STRATERGIES

TABLE 137.MANUS AKTTEVA BIOPHARMA LLP: COMPANY SNAPSHOT

TABLE 138.MANUS AKTTEVA BIOPHARMA LLP: OPERATING SEGMENTS

TABLE 139.MANUS AKTTEVA BIOPHARMA LLP: PRODUCT PORTFOLIO

TABLE 140.MANUS AKTTEVA BIOPHARMA LLP: NET SALES

TABLE 141.MANUS AKTTEVA BIOPHARMA LLP: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.TOXOPLASMOSIS TREATMENT MARKET SEGMENTATION

FIGURE 2.TOXOPLASMOSIS TREATMENT MARKET,2021-2031

FIGURE 3.TOXOPLASMOSIS TREATMENT MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.TOXOPLASMOSIS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.TOXOPLASMOSIS TREATMENT MARKET,BY TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ACQUIRED TOXOPLASMOSIS TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CONGENITAL TOXOPLASMOSIS TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)

FIGURE 15.TOXOPLASMOSIS TREATMENT MARKET,BY ROUTE OF ADMINISTRATION,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ORAL TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF PARENTERAL TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)

FIGURE 18.TOXOPLASMOSIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)

FIGURE 22.TOXOPLASMOSIS TREATMENT MARKET BY REGION,2021

FIGURE 23.U.S. TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 24.CANADA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 25.MEXICO TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 26.GERMANY TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 27.FRANCE TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 28.UK TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 29.ITALY TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 30.SPAIN TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 31.REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 32.JAPAN TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 33.CHINA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 34.INDIA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 35.AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 36.SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 37.REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 38.BRAZIL TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 39.SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 40.SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 41.REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)

FIGURE 42. TOP WINNING STRATEGIES, BY YEAR

FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 46.COMPETITIVE DASHBOARD

FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 48.ALVOGEN.: NET SALES ($MILLION)

FIGURE 49.DR REDDY'S LABORATORIES LTD..: NET SALES ($MILLION)

FIGURE 50.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)

FIGURE 51.VYERA PHARMACEUTICALS LLC.: NET SALES ($MILLION)

FIGURE 52.MANGALAM DRUGS AND ORGANICS LTD..: NET SALES ($MILLION)

FIGURE 53.OAKRUM PHARMA.: NET SALES ($MILLION)

FIGURE 54.KAISER PERMANENTE.: NET SALES ($MILLION)

FIGURE 55.ZORISH HEALTHCARE PRIVATE LIMITED.: NET SALES ($MILLION)

FIGURE 56.OMICRON PHARMACEUTICALS.: NET SALES ($MILLION)

FIGURE 57.MANUS AKTTEVA BIOPHARMA LLP.: NET SALES ($MILLION